NCT06925113View on ClinicalTrials.gov

A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in Taiwan

RecruitingOBSERVATIONAL
Enrollment

510

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

August 31, 2025

Study Completion Date

September 30, 2025

Conditions
Cervical CancersEndometrial CancerOvarian Cancer
Trial Locations (5)

100

RECRUITING

National Taiwan University Hospital, Taipei

104

RECRUITING

Mackay Memorial Hospital, Taipei

112

RECRUITING

Taipei Veterans General Hospital, Taipei

407

RECRUITING

Taichung Veterans General Hospital, Taichung

833

RECRUITING

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY